Endocrinologists are frequently asked to consult on inpatients with non-hypovolaemic hyponatraemia for whom initial fluid restriction has failed. This case-based talk will explore the second-line management options in these common, but frequently complex cases. There will be a critical focus on whether there is a routine hospital role for tolvaptan, the only TGA-approved vasopressin V2-receptor antagonist.